Online citations, reference lists, and bibliographies.
← Back to Search

Different Anthracycline Derivates For Reducing Cardiotoxicity In Cancer Patients.

E. C. van Dalen, E. Michiels, H. Caron, L. Kremer
Published 2006 · Mathematics, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND The use of anthracyclines is limited by the occurrence of cardiotoxicity. In an effort to prevent this cardiotoxicity, different anthracycline derivates have been studied. OBJECTIVES To determine the occurrence of cardiotoxicity with the use of different anthracycline derivates in cancer patients. SEARCH STRATEGY We searched The Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library, Issue 2, 2009), MEDLINE (1966 to 29 May 2009) and EMBASE (1980 to 2 June 2009). In addition, we searched reference lists of relevant articles, conference proceedings and ongoing-trials-databases. SELECTION CRITERIA Randomised controlled trials (RCTs) in which different anthracycline derivates were compared in cancer patients (children and adults). DATA COLLECTION AND ANALYSIS Two authors independently performed study selection, assessment of risk of bias and data-extraction including adverse effects. MAIN RESULTS We identified five RCTs of varying quality addressing epirubicin versus doxorubicin (1036 patients) with the same dose. The meta-analysis showed no evidence for a significant difference in the occurrence of clinical heart failure between the treatment groups (RR = 0.36, 95% CI 0.12 to 1.11). However, there is some suggestion of a lower rate of clinical heart failure in patients treated with epirubicin.We identified two RCTs with varying quality addressing liposomal-encapsulated doxorubicin versus conventional doxorubicin (521 patients). The meta-analysis showed a significantly lower rate of both clinical heart failure and clinical and subclinical heart failure combined in patients treated with liposomal-encapsulated doxorubicin (RR = 0.20, 95% CI 0.05 to 0.75 and RR = 0.38, 95% CI 0.24 to 0.59 respectively). It should be noted that in one of the studies patients in the liposomal-encapsulated doxorubicin group received a higher cumulative anthracycline dose than patients in the doxorubicin group.For the other possible combinations of different anthracycline derivates only one RCT (epirubicin versus liposomal-encapsulated doxorubicin) or no RCT was identified. AUTHORS' CONCLUSIONS We are not able to favour either epirubicin or doxorubicin when given with the same dose. Based on the currently available evidence on heart failure, we conclude that in adults with a solid tumour liposomal-encapsulated doxorubicin should be favoured over doxorubicin. For both epirubicin versus doxorubicin and liposomal-encapsulated doxorubicin versus conventional doxorubicin no conclusions can be made about the effects of treatment in children treated with anthracyclines and also not in patients diagnosed with leukaemia. More research is needed. For other combinations of anthracycline derivates not enough evidence was available to make definitive conclusions about the occurrence of cardiotoxicity in patients treated with anthracyclines.



This paper is referenced by
10.1093/annonc/mdn728
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
P. Barrett-Lee (2009)
10.5772/21239
Chemotherapy Toxicity in Patients with Acute Leukemia
J. Vagace (2011)
10.1177/1534735420945017
Platycodon grandiflorum Protects Against Anthracycline-Induced Cardiotoxicity in Early Breast Cancer Patients
W. Hao (2020)
10.1007/s11936-014-0312-7
Cardiac Complications of Chemotherapy: Role of Prevention
L. Magnano (2014)
Introducción a las complicaciones graves de la quimioterapia que debe enfrentar un cardiólogo
Patricia Avellana (2007)
10.1002/pbc.26375
Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis
P. Ananth (2017)
10.1016/J.REPCE.2012.11.019
Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention
R. Adão (2013)
10.1182/blood-2012-03-362608
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.
U. Creutzig (2012)
10.1517/14740338.2011.589834
Anthracycline cardiotoxicity
P. Menna (2012)
10.1186/s12885-015-1407-6
The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review
A. Conway (2015)
10.1111/j.1365-2141.2009.07624.x
Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.
T. Eden (2009)
10.1097/CAD.0b013e3283394624
Anticancer therapy induced cardiotoxicity: review of the literature
S. Geiger (2010)
10.1186/1471-2407-10-337
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
L. Smith (2010)
10.1159/000455823
Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview
P. Menna (2017)
10.1002/cncr.28061
Cardiac toxicity in cancer survivors
D. Lenihan (2013)
10.7150/jca.9132
Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
P. Vici (2014)
10.4081/hr.2011.s3.e6
SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly
M. Aapro (2011)
Exploration and application of nanomedicine in atherosclerotic disease
Mark E Lobatto (2016)
10.1177/030089160909500402
Non-Pegylated Liposomal Doxorubicin in Combination with Cyclophosphamide or Docetaxel as First-Line Therapy in Metastatic Breast Cancer: A Retrospective Analysis
L. Livi (2009)
10.3760/cma.j.issn.0253-2727.2016.12.007
聚乙二醇脂质体阿霉素在CHOP方案治疗侵袭性非霍奇金淋巴瘤中的Ⅰ期剂量递增试验的安全性探索
维娜 Weina 沈 Shen (2016)
10.1007/s00277-014-2250-6
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial
I. Wasle (2014)
10.1182/blood-2012-06-437178
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease.
S. Armenian (2012)
10.1002/pbc.22989
Echocardiographic surveillance for asymptomatic late‐onset anthracycline cardiomyopathy in childhood cancer survivors
Ibraheem Abosoudah (2011)
10.1097/HCO.0000000000000034
Anthracycline-related cardiotoxicity in childhood cancer survivors
S. Lipshultz (2014)
10.1124/jpet.117.242388
Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin
E. Salvatorelli (2017)
10.1080/08880010802016649
ANTHRACYCLINE CARDIOTOXICITY IN CHILDHOOD
A. Ruggiero (2008)
10.1111/jcpt.12124
Incidence and risk‐factors of CHOP/R‐CHOP‐related cardiotoxicity in patients with aggressive non‐Hodgkin's lymphoma
S. Limat (2014)
10.1097/CRD.0000000000000194
Cardioprotection in the Modern Era of Cancer Chemotherapy
A. Godishala (2018)
10.1016/j.ejca.2009.08.016
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
A. Constantinidou (2009)
10.1111/bjh.14374
Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?
M. Jarfelt (2016)
10.1093/eurheartj/ehs181
Cancer drugs and the heart: importance and management.
T. Suter (2013)
10.1097/FPC.0b013e32833ffb56
Doxorubicin pathways: pharmacodynamics and adverse effects
C. Thorn (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar